Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

Trial Details

NCT ID
NCT06082934
Phase
PHASE1 / PHASE2
Sponsor
Xijing Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Olverembatinib plus venetoclax and dexamethasone
Locations (sample)
  • Xi'an, Shannxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Diagnosis of newly-diagnosed Ph+ acute lymphoblastic leukemia
  • Age \>= 18
  • Adequate hepatic function
  • Adequate renal function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →